RP-1828 IMMUcan

PROJECT DESCRIPTION

IMMUcan-logo

IMMUcan – EORTC Research Project 1828- aims to generate broad molecular (WES and RNAseq) and cellular profiling data(multiplex IF and IMC) to better understand the tumour and its microenvironment, and the impact of current therapeutic interventions.

The project will recruit 3000 patients with head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), and Breast cancers (BC) via SPECTA, as well as thanks to collaborations with ongoing European external clinical trials for access to samples of utmost interest for the project.

For each patient enrolled, a free molecular report is generated within 6 weeks, containing the clinically relevant molecular alterations.

The IMMUcan consortium is an IMI initiative regrouping 32 academic and pharma partners: EORTC, Merck, SIB, EPF, IBBL, Bayer, CHUV, Katholieke Universiteit Leuven, Institut Curie, la ligue contre le cancer, Centre Léon Bérard, University of Zürich, Institut Jules Bordet, King’s College London, University of Birmingham, de Duve Institut, Charité, CRG, Owkin, Weizmann, Inserm, Abbvie, Lilly, GSK, Janssen, Sanofi, Pierre Fabre, Servier, CNAG, University of Paris, University of Warsaw, Novigenix (see more).

Several expert laboratories are involved in IMMUcan. The ones responsible for the broad profiling (analysis performed on all samples) are CeGaT (Tubingen, Germany), the Bodenmiller’s lab (Zurich, Switzerland), the CHUV (Lausanne, Switzerland) and CNAG.

For all patients enrolled in the project, a molecular report containing the clinically relevant molecular alterations will be shared with the treating clinician.

Patients with non-small cell lung cancer, head and neck  squamous cell carcinoma, breast cancer, renal cell carcinoma and colorectal cancer can be eligible for this project.

List of cohort

At enrollment:

FFPE Tissue: At least one FFPE block or a minimum 15 FFPE slides

Blood:1 serum tube, 3 ACD tubes, 1 BCT, 1 PAXgene RNA tube, 1 PAXgene DNA tube, 1 EDTA tube

At progression (please check for cohort-dependent specificities):

FFPE Tissue: At least one FFPE block or a minimum 15 FFPE slides (when possible, depending on tissue availability)

Blood: 1 serum tube, 3 ACD tubes, 1 BCT, 1 PAXgene RNA tube, 1 EDTA tube

Please visit the IMMUcan website for more information.

The IMMUcan project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821558. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA. Please visit the Immucan website for more information or contact the project team 1828@eortc.org.

  • Yes, IMMUcan! Unraveling the human tumor microenvironment
    (2021 – Immuno-Oncology Insights) Read more

LIST OF COHORTS

For SPECTA, please enroll patients with the tumor type specified in the table, ONLY when the status is green. You can enroll those patients by clicking on the , next to the green status.
Study specific information (HBM, Project Specific selection criteria, CRF completion guidelines…) can be found here . Please note that your electronic database ORTA password is required for access (protocol 1553).

For any questions, please contact the project address: 1828@eortc.org.

To view the List of Cohorts, please flip your mobile phone horizontally:

Primary disease Status

  • Patients with confirmed locally advanced or metastatic NSCLC (stage from IIIb to IV),
  • Patient naive of systemic treatment (in the adjuvant or metastatic settings),
  • Patient to be treated in 1st line (either TKI, ICI alone or ICI/chemotherapy), as per standard of care
  • Patients diagnosed with early stage NSCLC (I-IIIB), but progressing within 6 months will be accepted, considered as occult metastatic disease. Note: diagnosis/surgery samples can be accepted.
 Open

Primary disease Status
Cohort 1

  • Patients with confirmed locally advanced and/or recurrent and/or metastatic HNSCC,
  • Patient to be treated in 1st line, with focus on ICI/ICI-chemo once approved in Europe,
  • Or patient resistant to platinum, to be treated with ICI/ICI-chemo in 2nd line
 Open
Cohort 2

  • HNSCC patients with confirmed progression less than 1 year after treatment with chemo-radiation, radiation only, bioradiation (of note, patients with prior surgery(ies) are also eligible)
  • Enrolled at time of salvage surgery
 Open

Primary disease Status
Cohort 1

  • Patients with confirmed locally advanced or metastatic Triple Negative Breast Cancer (TNBC),
  • Patient naive of treatment (in the metastatic settings),
  • Patient to be treated in 1st line with focus on ICI/ICI-chemo
 Open
Cohort 2

  • Patients with confirmed diagnostic of localized TNBC (stage I to III) breast cancer,
  • To be treated with neo-adjuvant therapy,
  • Registered prior to neo-adjuvant chemotherapy
 Open
Cohort 3

  • Patients with confirmed diagnosis of localized HER2+ (stage I to III) breast cancer,
  • To be treated with neo-adjuvant therapy,
  • Registered prior to neo-adjuvant chemotherapy
 Open

Primary disease Status
  • Patients with a confirmed diagnostis of metastatic, colorectal adenocarcinoma,
  • Planned biopsy and/or resection of the metastatic sites,
  • Archival primary tumor tissue/or fresh biopsy (as per standard of care) available
    Analysis will be planned based on number of metastatic sites and/or number of lesions
 Open

Primary disease Status

  • Patients with confirmed metastatic RCC,
  • Naïve of treatment (in the metastatic settings),
  • To be treated in 1st line,
  • Or high risk patient pT4, any grade, N0 M0; or any pT any grade, N+ M0 (TNM staging) treated in adjuvant setting with ICI
 Open
BACK TO PROJECTS